B群脑膜炎球菌疫苗开发与临床前评价（续）  

Development and preclinical evaluation of vaccines against group B meningococcus （continued）

作　　者：吴根鹏[1] 朱为(综述)[1] 

机构地区：[1]上海生物制品研究所有限责任公司第三研究室,200052

出　　处：《国际生物制品学杂志》2013年第6期308-311,321,共5页International Journal of Biologicals

摘　　要：脑膜炎球菌（Neisseria meningitidis,Nm）感染可导致流行性脑脊髓膜炎和败血症,有较高的病死率.荚膜多糖及多糖结合疫苗能有效控制A、C、W135和Y群Nm感染,而对B群Nm （MenB）感染的预防,只有外膜囊泡疫苗在局部地区取得成功.目前,针对MenB疫苗的研究以外膜蛋白为基础.此文对MenB疫苗的研发进展及临床前研究中的几个关键评价指标进行综述.Neisseria meningitidis （Nm） is a major cause of epidemic cerebrospinal meningitis and septicemia with high fatality rates.Effective polysaccharide vaccines and conjugate vaccines have been developed to control the infections caused by groups A,C,W135 and Y Nm,but there are no commonly used,effective vaccines against group B Nm （MenB） except that several outer membrane vesicles based vaccines are effective in certain areas.Current vaccine strategies are focused on outer membrane proteins.This paper reviews the progress in development of MenB vaccines and some key points of preclinical evaluation.

关 键 词：奈瑟球菌 脑膜炎 血清B群 疫苗 细菌外膜蛋白质类 

分 类 号：R392[医药卫生—免疫学]